George Davis

Feb 17, 2017

Perthera has appointed George Davis to its board of directors. Davis currently serves as CEO of Gemstone Biotherapeutics. Previously, he served as president and vice chairman of Aether Systems. He has also served as CEO and director of Avatech Solutions.

More Like This

Apr 20, 2018

William Bonello

NeoGenomics has appointed William Bonello VP of strategy, corporate development and investor relations. Bonello has served as the company's VP, treasurer, and director of corporate development since April of last year. Previously Bonello worked as a healthcare equity analyst covering diagnostic services and product stocks for Craig-Hallum, and as an equity analyst for Piper Jaffray, Wachovia Securities, and RBC Capital Markets. Bonello was also previously senior VP for investor relations at Laboratory Corporation of America.

Apr 18, 2018

Linda McAllister

Linda McAllister has been named CMO of Revelar Health, which is developing a breath-based test to measure aldehyde concentrations. McAllister was previously the VP of scientific affiars and innovations at Becton Dickinson. Before that, she was a consultant to early-stage device and diagnostic companies. She also has been CMO at Xagenic, CellScape, PharmaJet, and Arbor Vita. 

Apr 16, 2018

John Lubniewski

John Lubniewski has been promoted by HTG Molecular Diagnostics to president and chief operating officer. Lubniewski has been the company's chief business officer for the past seven years. He joined HTG from Ventana, now part of Roche, where he held several senior leadership roles, and was responsible for marketing and global accountability for all assay products. Prior to joining Ventana, he was with Corning.

Apr 16, 2018

Michael Ropacki

Amarantus Bioscience appointed Michael Ropacki as chief medical advisor to its alzheimer's blood diagnostic LymPro test program. Ropacki will be responsible for helping oversee the further development of LymPro. He will also assist a management team currently being recruited to lead the firm's neurodiagnostics division in raising capital for a neurodiagnostics subsidiary that it will soon establish. Amarantus noted that Ropacki brings more than 20 years of clinical development experience as a clinical leader, investigator, and consultant.

Apr 16, 2018

Richard Williams

Richard Williams has become managing director and head of oncology programs at WuXi Nextcode. He joins the company from Grail, where he was lead medical director of the Circulating Cell-Free Genome Atlas program. Prior to that, he held positions in oncology drug development at Amgen and at Puma Technology. Williams holds B.Med.Sc and PhD degrees, as well as bachelor of medicine and bachelor of surgery degrees, from the University of Queensland in Australia.

Apr 13, 2018

Irwin Jacobs, Martin Wygod

Biological Dynamics has added Irwin Jacobs and Martin Wygod to its board of directors. Jacobs is a cofounder of semiconductor and telecommunications equipment firm Qualcomm, as well as chairman emeritus of the Salk Institute for Biological Studies. Wygod is director of Medco Containment Services and former chairman of WebMD Health. 

Apr 13, 2018

Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, Robin Patel

Curetis has established a US scientific advisory board consisting of five infectious disease experts. Debra Goff, Donna Mildvan, Melissa Miller, Frederick Nolte, and Robin Patel will support the clinical adoption of the firm's Unyvero System and lower respiratory tract infection assay recently cleared by the US Food and Drug Administration. 

Goff is currently an infectious diseases specialist with the One Health Antibiotic Stewardship team at The Ohio State University; Mildvan is professor of medicine at Icahn School of Medicine at Mount Sinai in New York; Miller is director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine; Nolte is medical director of clinical labs and molecular pathology at the Medical University of South Carolina; and Patel is co-director of the clinical bacteriology laboratory, director of the infectious diseases research lab, and chair of the division of clinical microbiology at Mayo Clinic.

Apr 13, 2018

Heidi Rehm

Heidi Rehm last month became chief genomics officer in the Department of Medicine at Massachusetts General Hospital, where she is part of the Center for Genomic Medicine. In her new role, she will focus on the clinical implementation of genomics. Rehm remains medical director of the Broad Institute’s clinical research sequencing platform and an associate professor of pathology at MGH, Brigham and Women’s Hospital, and Harvard Medical School. She is also a leader and principal investigator of ClinGen, and a co-leader of the Broad Center for Mendelian Genomics. Previously, Rehm was the director of the Laboratory for Molecular Medicine at Partners Healthcare Personalized Medicine.

Apr 13, 2018

Michael Murray

Michael Murray has become director for clinical operations in the Center for Genomic Health at Yale University School of Medicine. He joins Yale from the Geisinger Health System, where he was director of clinical genomics and was leading the GenomeFIRST return of results program, which is part of Geisinger’s MyCode Community Heath Initiative. In his new role at Yale, he will similarly focus on bringing clinical genomics to large patient cohorts.

Apr 11, 2018

Kenneth Berlin

Rosetta Genomics President and CEO Kenneth Berlin is resigning from the company effective April 18 to pursue other opportunities. He will assist the company in a smooth transition with ongoing projects, the company said. Berlin joined Rosetta Genomics in November 2009 as president and CEO. Before that, he was worldwide general manager at Veridex, a Johnson & Johnson company. He joined J&J in 1994 and was its corporate counsel for six years, according to Rosetta Genomics' website. From 2001 to 2004, he was vice president of licensing and new business development in the pharmaceutical group at J&J, and from 2004 to 2007, he was worldwide VP of franchise development at Ortho Clinical Diagnostics, also a J&J company. 

Apr 10, 2018

James Mock

PerkinElmer has appointed James Mock as senior vice president and CFO, effective May 1. Mock will replace Andy Wilson as CFO. Wilson, who previously announced his retirement from PerkinElmer, will remain with the company as an advisor for an interim period to ensure a smooth integration, the firm said. Mock has served for nearly 20 years in a wide range of financial oversight capacities within General Electric, most recently as vice president of GE's corporate audit staff, where he worked on controllership reviews and operational excellence projects. 

Apr 10, 2018

David Rappaport

OraSure Technologies has appointed David Rappaport senior vice president of business development. He had been senior vice president, healthcare investment banking at Raymond James. Prior to that, Rappaport was a healthcare investment banker with Inverness Advisors, Theomas Weisel Partners, and SG Cowen. 

Apr 10, 2018

Matthew Strobeck

Quidel has appointed Matthew Strobeck, managing partner of Birchview Capital, to the company's board of directors after increasing the size of its board from seven to eight members. Strobeck was previously with Westfield Capital Management and currently serves on the boards of Accelerate Diagnostics and Biodesix.

Apr 10, 2018

Dirk Ehlers

Centogene has appointed Dirk Ehlers its chief operating officer and president of the diagnostics division. He joins the company from Hill-Rom Holdings where he was senior vice president and president of the sugical solutions division and served on the Group Executive Team. Before that, he was CEO of Eppendorf, and he has held management positions at Roche, Fresenius Kabi, Olympus Optical, and Evotec.

Apr 09, 2018

Tom Lindsay

Genedrive has appointed Tom Lindsay as a non-executive director, effective immediately. Lindsay most recently was at Alere, where he held roles including president of Africa, president of commercial operations in Africa, and business development director for Africa, before he retired in 2017. Prior to Alere, he held senior commercial roles at Trinity Biotech.